Skip to main content

Advertisement

Log in

Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Aims

This study aimed to evaluate the effect of pioglitazone on brown adipose tissue function and hypothalamic gliosis in humans. Brown adipose tissue and the hypothalamus are regarded as important potential pharmacological targets to metabolic diseases, and defining the impact of current therapies on their structure and/or function could provide therapeutic advance in this field.

Methods

Six patients with type 2 diabetes were treated for 24 weeks with pioglitazone 30 mg/day as an add-on therapy. Brown adipose tissue glucose uptake and volume were determined using 18F-FDG PET/CT scans; hypothalamic gliosis was determined using MRI scans; blood was collected for hormone and biochemistry measurements. All tests were performed at inclusion and six months after pioglitazone introduction.

Results

Pioglitazone treatment led to a significant 3% body mass increase. There were neither changes in cold-induced brown adipose tissue glucose uptake and volume nor changes in hypothalamic gliosis.

Conclusions

This is a proof-of-concept study that provides clinical evidence for a lack of action of a thiazolidinedione, pioglitazone, to promote homogeneous and measurable changes in brown adipose tissue volume and also in hypothalamic gliosis after 6 months of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Stanford KI, Middelbeek RJ, Townsend KL et al (2013) Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest. 123(1):215–223

    Article  CAS  PubMed  Google Scholar 

  2. Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84(1):277–359

    Article  CAS  PubMed  Google Scholar 

  3. Chen KY, Cypess AM, Laughlin MR et al (2016) Brown adipose reporting criteria in Imaging STudies (BARCIST 1.0): recommendations for standardized FDG-PET/CT experiments in humans. Cell Metab 24(2):210–222

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. de-Lima-Júnior JC, Souza GF, Moura-Assis A et al (2019) Abnormal brown adipose tissue mitochondrial structure and function in IL10 deficiency. EBioMedicine 39:436–447

    Article  PubMed  Google Scholar 

  5. Rodovalho S, Rachid B, De-Lima-Junior JC et al (2017) Impairment of body mass reduction-associated activation of brown/beige adipose tissue in patients with type 2 diabetes mellitus. Int J Obes (Lond). 41(11):1662–1668

    Article  CAS  Google Scholar 

  6. Monroy A, Kamath S, Chavez AO et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52(10):2169–2181

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Association AD (2014) Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl 1):S14–S80

    Article  Google Scholar 

  8. Tahari AK, Chien D, Azadi JR, Wahl RL (2014) Optimum lean body formulation for correction of standardized uptake value in PET imaging. J Nucl Med 55(9):1481–1484

    Article  PubMed  PubMed Central  Google Scholar 

  9. Sewaybricker LE, Schur EA, Melhorn SJ et al (2019) Initial evidence for hypothalamic gliosis in children with obesity by quantitative T2 MRI and implications for blood oxygen-level dependent response to glucose ingestion. Pediatr Obes. 14(2):e12486

    PubMed  Google Scholar 

  10. Landecho MF, Colina I, Sunsundegui P, Camarero B, Núñez-Córdoba JM, Beloqui Ó (2019) Comparison of correlations of equation-derived body fat percentage and body mass index with carotid intima-media thickness. Acta Diabetol 56(3):373–375

    Article  PubMed  Google Scholar 

  11. Wang S, Wang Z, Chen C et al (2019) Contribution of epicardial and abdominopelvic visceral adipose tissues in Chinese adults with impaired glucose regulation and diabetes. Acta Diabetol 56(9):1061–1071

    Article  CAS  PubMed  Google Scholar 

  12. Higgins PB, Folli F, Andrade MCR et al (2019) Duodenal adipose tissue is associated with obesity in baboons (Papio sp): a novel site of ectopic fat deposition in non-human primates. Acta Diabetol 56(2):227–236

    Article  PubMed  Google Scholar 

  13. Moreno-Galdós L, Barba-Cosials J, Núñez-Córdoba JM (2018) Association between echocardiographic epicardial adipose tissue and E/e′ ratio in obese adults. Acta Diabetol 55(1):103–106

    Article  PubMed  Google Scholar 

  14. Loh RKC, Formosa MF, Eikelis N et al (2018) Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans. Diabetologia 61(1):220–230

    Article  CAS  PubMed  Google Scholar 

  15. Festuccia WT, Blanchard PG, Richard D, Deshaies Y (2010) Basal adrenergic tone is required for maximal stimulation of rat brown adipose tissue UCP1 expression by chronic PPAR-gamma activation. Am J Physiol Regul Integr Comp Physiol 299(1):R159–R167

    Article  CAS  PubMed  Google Scholar 

  16. Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H (1987) Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats. Diabetes 36(1):6–13

    Article  CAS  PubMed  Google Scholar 

  17. Lefebvre AM, Laville M, Vega N et al (1998) Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47(1):98–103

    Article  CAS  PubMed  Google Scholar 

  18. Tripathy D, Daniele G, Fiorentino TV et al (2013) Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56(10):2153–2163

    Article  CAS  PubMed  Google Scholar 

  19. Armato JP, DeFronzo RA, Abdul-Ghani M, Ruby RJ (2018) Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). Lancet Diabetes Endocrinol. 6(10):781–789

    Article  PubMed  Google Scholar 

  20. Hanssen MJ, Hoeks J, Brans B et al (2015) Short-term cold acclimation improves insulin sensitivity in patients with type 2 diabetes mellitus. Nat Med 21(8):863–865

    Article  CAS  PubMed  Google Scholar 

  21. Diano S, Liu ZW, Jeong JK et al (2011) Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med 17(9):1121–1127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Rachid B, van de Sande-Lee S, Rodovalho S et al (2015) Distinct regulation of hypothalamic and brown/beige adipose tissue activities in human obesity. Int J Obes (Lond). 39(10):1515–1522

    Article  CAS  Google Scholar 

  23. Thaler JP, Yi CX, Schur EA et al (2012) Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 122(1):153–162

    Article  CAS  PubMed  Google Scholar 

  24. van de Sande-Lee S, Melhorn SJ, Rachid B et al (2019) Radiologic evidence that hypothalamic gliosis is improved after bariatric surgery in obese women with type 2 diabetes. Int J Obes (Lond). https://doi.org/10.1038/s41366-019-0399-8

Download references

Funding

This research was sponsored by GSK (GlaxoSmithKline plc). This research was also supported by the São Paulo Research Foundation (FAPESP 2013/076078).

Author information

Authors and Affiliations

Authors

Contributions

JCLJ drafted the first version of the manuscript. JCLJ, FF and LV wrote the manuscript. JCLJ, FF and LV edited and reviewed the manuscript. JCLJ, RMC and MMP performed the statistical analyses, reviewed/edited the manuscript and researched the data. JCLJ and MMP performed PET/CT analysis. CDR performed PET/CT scanning. FC performed MRI scanning and edited partially the manuscript. SVSL performed MRI analysis. LV, SR and BR conceived the design of the study. JCLJ, SR and BR recruited and assisted the patients.

Corresponding author

Correspondence to Lício A. Velloso.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

The study was approved by the local medical ethical committee of the University of Campinas (Ethics Committee approval CAAE: 32930314.8.0000.5404).

Informed consent

All patients being enrolled into this registry provided written informed consent.

Additional information

Managed By Massimo Federici.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 3924 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de-Lima-Júnior, J.C., Rodovalho, S., Van de Sande-Lee, S. et al. Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study. Acta Diabetol 56, 1333–1339 (2019). https://doi.org/10.1007/s00592-019-01418-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-019-01418-2

Keywords

Navigation